MT-1303
MT-1303 is a pharmaceutical drug with 6 clinical trials. Historical success rate of 100.0%.
Success Metrics
Based on 6 completed trials
Phase Distribution
Phase Distribution
3
Early Stage
3
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
100.0%
6 of 6 finished
0.0%
0 ended early
0
trials recruiting
6
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Study Evaluating Efficacy and Safety of Amiselimod (MT-1303) in Mild to Moderate Ulcerative Colitis
Extension Study of MT-1303 in Subjects With Crohn's Disease
Safety and Efficacy of MT-1303 in Subjects With Moderate to Severe Active Crohn's Disease
Mass Balance Study of MT-1303
Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety Study of MT-1303 in Subjects With Crohn's Disease
Clinical Trials (6)
Study Evaluating Efficacy and Safety of Amiselimod (MT-1303) in Mild to Moderate Ulcerative Colitis
Extension Study of MT-1303 in Subjects With Crohn's Disease
Safety and Efficacy of MT-1303 in Subjects With Moderate to Severe Active Crohn's Disease
Mass Balance Study of MT-1303
Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety Study of MT-1303 in Subjects With Crohn's Disease
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of MT-1303 in Subjects With Inflammatory Bowel Disease
All 6 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 6